Sequential Application of Yisaipu® and DMARDs in Treating Mild-to-Moderate AS
Status:
Completed
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
The drug regimes in treating ankylosing spondylitis(AS) have limitations. The tumor necrosis
factor inhibitors(TNFi) was effective but expensive. Disease modifying anti-rheumatic drugs
(DMARDs) were cheap but insufficient. This study proposed a sequential usage of TNFi, the
Yisaipu®, and DMARDs, and aims to evaluate the mid-term therapeutic effect of this new scheme
in treating the mild-to-moderate AS.